European Commission Expands Merck’s ERVEBO®Indication to Include Children 1 Year of Age and Older
European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older Merck known as MSD outside of the United States and…
Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular…
Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research
Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research With cancer patients top of…
Dr. Patrick Fox Named President of Amerigroup New Jersey
Dr. Patrick Fox Named President of Amerigroup New Jersey Amerigroup New Jersey, a wholly owned subsidiary of Elevance Health and one of New Jersey’s largest coordinators of Medicaid managed care…
First-in-class targeted microRNA therapy slows cancer tumor growth
First-in-class targeted microRNA therapy slows cancer tumor growth A new cancer therapy developed by Purdue University researchers attacks tumors by tricking cancer cells into absorbing a snippet of RNA that…
Why breast cancer survivors don’t take their medication, and what can be done
Why breast cancer survivors don’t take their medication, and what can be done For roughly 80% of breast cancer survivors, treatment doesn’t end with surgery, radiation and chemotherapy. Instead, for…
Roche’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
Roche’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer Roche announced today that the Phase III ALINA study evaluating Alecensa® (alectinib), compared with platinum-based chemotherapy,…
AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION
AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION Amgen and Horizon Therapeutics plc today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that…
AMGEN TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE AND THE CITI GLOBAL HEALTHCARE CONFERENCE
AMGEN TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE AND THE CITI GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the 2023 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Wednesday, Sept. 6, 2023. Amgen will…
Sanofi announces changes to its Executive Committee
Sanofi announces changes to its Executive Committee Houman, Madeleine and Emmanuel will report to Sanofi’s CEO, Paul Hudson, and will be based in Paris, France. Brian, also reporting to Paul…
Bayer to invest EUR 220 million in new R&D facility at its Monheim site
Bayer to invest EUR 220 million in new R&D facility at its Monheim site Bayer significantly strengthens its commitment to innovation in regenerative agriculture with a EUR 220 million investment in research…
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA Plus LENVIMA in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA Plus LENVIMA® in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Merck…